TransCode Therapeutics Inc (NASDAQ: RNAZ) started the day on Wednesday, with a price increase of 10.33% at $0.67, before settling in for the price of $0.61 at the close. Taking a more long-term approach, RNAZ posted a 52-week range of $0.22-$20.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -28.81%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 98.01%. This publicly-traded company’s shares outstanding now amounts to $17.27 million, simultaneously with a float of $17.23 million. The organization now has a market capitalization sitting at $11.62 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4207, while the 200-day Moving Average is $0.8048.
TransCode Therapeutics Inc (RNAZ) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. TransCode Therapeutics Inc’s current insider ownership accounts for 0.19%, in contrast to 11.46% institutional ownership.
TransCode Therapeutics Inc (RNAZ) Earnings and Revenue Records
TransCode Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 98.01% and is forecasted to reach -0.60 in the upcoming year.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Let’s observe the current performance indicators for TransCode Therapeutics Inc (RNAZ). It’s Quick Ratio in the last reported quarter now stands at 1.25. The Stock has managed to achieve an average true range (ATR) of 0.10.
In the same vein, RNAZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -75.05, a figure that is expected to reach -0.49 in the next quarter, and analysts are predicting that it will be -0.60 at the market close of one year from today.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
If we take a close look at the recent performances of TransCode Therapeutics Inc (NASDAQ: RNAZ), its last 5-days Average volume was 0.95 million that shows plunge from its year to date volume of 1.31 million. During the previous 9 days, stock’s Stochastic %D was recorded 39.50% While, its Average True Range was 0.1033.
Raw Stochastic average of TransCode Therapeutics Inc (RNAZ) in the period of the previous 100 days is set at 29.03%, which indicates a major fall in contrast to 68.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 170.99% that was lower than 220.87% volatility it exhibited in the past 100-days period.
